Grazoprevir potassium

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 330132

CAS#: 1206524-86-8 (potassium)

Description: Grazoprevir, also known as MK5172, is a drug approved for the treatment of hepatitis C. Grazoprevir is a second generation hepatitis C virus protease inhibitor acting at the NS3/4a protease targets. It has good activity against a range of HCV genotype variants, including some that are resistant to most currently used antiviral medications.

Price and Availability


USD 450
USD 2950

USD 850
USD 4250

USD 1650
USD 7450

Grazoprevir potassium, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 330132
Name: Grazoprevir potassium
CAS#: 1206524-86-8 (potassium)
Chemical Formula: C38H49KN6O9S
Exact Mass:
Molecular Weight: 805.0
Elemental Analysis: C, 56.70; H, 6.14; K, 4.86; N, 10.44; O, 17.89; S, 3.98

Related CAS #: 1350514-68-9 (free)   1350462-55-3 (hydrate)   1206524-86-8 (potassium)    

Synonym: MK 5172 potassium; MK-5172; MK 5172; MK5172; Grazoprevir; Grazoprevir potassium; Grazoprevir hydrate; trade name: Zepatier‎.

IUPAC/Chemical Name: potassium ((1R,2S)-1-((33R,35S,91R,92R,5S)-5-(tert-butyl)-17-methoxy-4,7-dioxo-2,8-dioxa-6-aza-1(2,3)-quinoxalina-3(3,1)-pyrrolidina-9(1,2)-cyclopropanacyclotetradecaphane-35-carboxamido)-2-vinylcyclopropane-1-carbonyl)(cyclopropylsulfonyl)amide


InChi Code: InChI=1S/C38H50N6O9S.K/c1-6-22-19-38(22,35(47)43-54(49,50)25-13-14-25)42-32(45)29-18-24-20-44(29)34(46)31(37(2,3)4)41-36(48)53-30-16-21(30)10-8-7-9-11-27-33(52-24)40-28-17-23(51-5)12-15-26(28)39-27;/h6,12,15,17,21-22,24-25,29-31H,1,7-11,13-14,16,18-20H2,2-5H3,(H3,41,42,43,45,47,48);/q;+1/p-1/t21-,22-,24-,29+,30-,31-,38-;/m1./s1

SMILES Code: COC1=CC2=NC3=C(CCCCC[C@@H]4C[C@H]4OC(N[C@@H](C(C)(C)C)C(N5C[C@H](O3)C[C@H]5C(N[C@]6(C([N-]S(=O)(C7CC7)=O)=O)C[C@H]6C=C)=O)=O)=O)N=C2C=C1.[K+]

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Yeh WW, Fraser IP, Jumes P, Petry A, Lepeleire I, Robberechts M, Reitmann C, Van Dyck K, Huang X, Guo Z, Panebianco D, Nachbar RB, O'Mara E, Wagner JA, Butterton JR, Dutko FJ, Moiseev V, Kobalava Z, Hüser A, Visan S, Schwabe C, Gane E, Popa S, Ghicavii N, Uhle M, Wagner F. Antiviral Activity, Safety, and Tolerability of Multiple Ascending Doses of Elbasvir or Grazoprevir in Participants Infected With Hepatitis C Virus Genotype-1 or -3. Clin Ther. 2018 Apr 24. pii: S0149-2918(18)30094-8. doi: 10.1016/j.clinthera.2018.03.002. [Epub ahead of print] PubMed PMID: 29703432.

2: Zamor PJ, Vierling J, Ghalib R, Luketic V, Ravendhran N, Balart L, Robertson M, Hwang P, Hanna GJ, Nguyen BY, Barr E, Talwani R, Pearlman B. Elbasvir/grazoprevir in black adults with hepatitis C virus infection: a pooled analysis of phase 2/3 clinical trials. Am J Gastroenterol. 2018 Apr 26. doi: 10.1038/s41395-018-0053-4. [Epub ahead of print] PubMed PMID: 29695828.

3: Flamm SL, Bacon B, Curry MP, Milligan S, Nwankwo CU, Tsai N, Younossi Z, Afdhal N. Real-world use of elbasvir-grazoprevir in patients with chronic hepatitis C: retrospective analyses from the TRIO network. Aliment Pharmacol Ther. 2018 Apr 17. doi: 10.1111/apt.14635. [Epub ahead of print] PubMed PMID: 29665097.

4: Kanda T, Yasui S, Nakamura M, Nakamoto S, Takahashi K, Wu S, Sasaki R, Haga Y, Ogasawara S, Saito T, Kobayashi K, Kiyono S, Ooka Y, Suzuki E, Chiba T, Maruyama H, Moriyama M, Kato N. Successful retreatment with grazoprevir and elbasvir for patients infected with hepatitis C virus genotype 1b, who discontinued prior treatment with NS5A inhibitor-including regimens due to adverse events. Oncotarget. 2018 Mar 23;9(22):16263-16270. doi: 10.18632/oncotarget.24620. eCollection 2018 Mar 23. PubMed PMID: 29662642; PubMed Central PMCID: PMC5882333.

5: Weiss L, Wustmann K, Semmo M, Schwerzmann M, Semmo N. Elbasvir/Grazoprevir, an Alternative in Antiviral Hepatitis C Therapy in Patients under Amiodarone Treatment. Case Rep Gastroenterol. 2018 Feb 21;12(1):92-98. doi: 10.1159/000486951. eCollection 2018 Jan-Apr. PubMed PMID: 29606942; PubMed Central PMCID: PMC5869552.

6: Kiang TKL. Clinical Pharmacokinetics and Drug-Drug Interactions of Elbasvir/Grazoprevir. Eur J Drug Metab Pharmacokinet. 2018 Mar 20. doi: 10.1007/s13318-018-0471-0. [Epub ahead of print] PubMed PMID: 29557529.

7: Maunoury F, Clément A, Nwankwo C, Levy-Bachelot L, Abergel A, Di Martino V, Thervet E, Durand-Zaleski I. Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France. PLoS One. 2018 Mar 15;13(3):e0194329. doi: 10.1371/journal.pone.0194329. eCollection 2018. PubMed PMID: 29543897; PubMed Central PMCID: PMC5854359.

8: Foster GR, Agarwal K, Cramp ME, Moreea S, Barclay S, Collier J, Brown AS, Ryder SD, Ustianowski A, Forton DM, Fox R, Gordon F, Rosenberg WM, Mutimer DJ, Du J, Gilbert CL, Asante-Appiah E, Wahl J, Robertson MN, Barr E, Haber B. Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial. Hepatology. 2018 Feb 23. doi: 10.1002/hep.29852. [Epub ahead of print] PubMed PMID: 29473975.

9: Asselah T, Reesink H, Gerstoft J, de Ledinghen V, Pockros PJ, Robertson M, Hwang P, Asante-Appiah E, Wahl J, Nguyen BY, Barr E, Talwani R, Serfaty L. Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysis. Liver Int. 2018 Feb 20. doi: 10.1111/liv.13727. [Epub ahead of print] PubMed PMID: 29461687.

10: Tarao K, Sato A. A Hepatitis C Virus-Associated Chronic Hepatitis Patient Developing Various Adverse Events Including Severe Gingivitis, Gingival Bleeding, and Inflammation of Genital Vulva during the Course of Antiviral Therapy with Elbasvir/Grazoprevir. Case Rep Gastroenterol. 2017 Nov 29;11(3):736-741. doi: 10.1159/000484135. eCollection 2017 Sep-Dec. PubMed PMID: 29430226; PubMed Central PMCID: PMC5803708.

11: Reau N, Robertson MN, Feng HP, Caro L, Yeh WW, Nguyen BT, Wahl J, Barr E, Hwang P, Klopfer SO. Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir: A pooled analysis of 1,322 patients with hepatitis C infection. Hepatol Commun. 2017 Aug 22;1(8):757-764. doi: 10.1002/hep4.1081. eCollection 2017 Oct. PubMed PMID: 29404492; PubMed Central PMCID: PMC5678913.

12: Husa P, Husová L. [First experience with elbasvir/grazoprevir fixed-dose combination in real-life practice in the Czech Republic]. Klin Mikrobiol Infekc Lek. 2017 Dec;23(4):137-141. Czech. PubMed PMID: 29378382.

13: Zeuzem S, Serfaty L, Vierling J, Cheng W, George J, Sperl J, Strasser S, Kumada H, Hwang P, Robertson M, Wahl J, Barr E, Talwani R, Platt H. The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection. J Gastroenterol. 2018 May;53(5):679-688. doi: 10.1007/s00535-018-1429-3. Epub 2018 Jan 17. PubMed PMID: 29344726.

14: Feng HP, Caro L, Fandozzi CM, Guo Z, Talaty J, Wolford D, Panebianco D, Iwamoto M, Butterton JR, Yeh WW. Pharmacokinetic Interactions Between Elbasvir/Grazoprevir and Immunosuppressant Drugs in Healthy Volunteers. J Clin Pharmacol. 2018 May;58(5):666-673. doi: 10.1002/jcph.1052. Epub 2018 Jan 12. PubMed PMID: 29329497.

15: Ahmed H, Abushouk AI, Menshawy A, Attia A, Mohamed A, Negida A, Abdel-Daim MM. Meta-Analysis of Grazoprevir plus Elbasvir for Treatment of Hepatitis C Virus Genotype 1 Infection. Ann Hepatol. 2018 January-February;17(1):18-32. doi: 10.5604/01.3001.0010.7532. PubMed PMID: 29311409.

16: Brown A, Hézode C, Zuckerman E, Foster GR, Zekry A, Roberts SK, Lahser F, Durkan C, Badshah C, Zhang B, Robertson M, Wahl J, Barr E, Haber B; C-SCAPE Study Investigators. Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C-SCAPE study. J Viral Hepat. 2018 May;25(5):457-464. doi: 10.1111/jvh.12801. Epub 2018 Mar 14. PubMed PMID: 29152828.

17: de Lédinghen V, Laforest C, Hézode C, Pol S, Renault A, Alric L, Larrey D, Métivier S, Tran A, Jézéquel C, Samuel D, Zoulim F, Tual C, Pailhé A, Gibowski S, Bourlière M, Bellissant E, Pawlotsky JM. Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study. Clin Infect Dis. 2018 Mar 19;66(7):1013-1018. doi: 10.1093/cid/cix916. PubMed PMID: 29077864.

18: Xu F, Zhong YL, Li H, Qi J, Desmond R, Song ZJ, Park J, Wang T, Truppo M, Humphrey GR, Ruck RT. Asymmetric Synthesis of Functionalized trans-Cyclopropoxy Building Block for Grazoprevir. Org Lett. 2017 Nov 3;19(21):5880-5883. doi: 10.1021/acs.orglett.7b02867. PubMed PMID: 29052413.

19: Corman S, Elbasha EH, Michalopoulos SN, Nwankwo C. Cost-Utility of Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1 Infection. Value Health. 2017 Sep;20(8):1110-1120. doi: 10.1016/j.jval.2017.05.003. Epub 2017 Jun 20. PubMed PMID: 28964443.

20: Karaoui LR, Mansour H, Chahine EB. Elbasvir-grazoprevir: A new direct-acting antiviral combination for hepatitis C. Am J Health Syst Pharm. 2017 Oct 1;74(19):1533-1540. doi: 10.2146/ajhp160558. Review. PubMed PMID: 28947524.